Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
40
HCM Quote, Financials, Valuation and Earnings
Last price:
$15.14
Seasonality move
:
-2.08%
Day range:
$14.70 - $15.39
52-week range:
$11.51 - $19.50
Dividend yield:
0%
P/E ratio:
4.92x
P/S ratio:
4.42x
P/B ratio:
2.67x
Volume:
6.5K
Avg. volume:
39.2K
1-year change:
-0.26%
Market cap:
$2.6B
Revenue:
$630.5M
EPS (TTM):
$2.66
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
HCM
HUTCHMED (China) Ltd.
|
-- | -- | -- | -- | $21.11 |
|
CKLSF
CK Life Sciences International (Holdings), Inc.
|
-- | -- | -- | -- | -- |
|
LJUIF
SSY Group Ltd.
|
-- | -- | -- | -- | -- |
|
RGC
Regencell Bioscience Holdings Ltd.
|
-- | -- | -- | -- | -- |
|
SBMFF
Sino Biopharmaceutical Ltd.
|
-- | -- | -- | -- | -- |
|
UNBSF
Uni-Bio Science Group
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
HCM
HUTCHMED (China) Ltd.
|
$15.29 | $21.11 | $2.6B | 4.92x | $0.00 | 0% | 4.42x |
|
CKLSF
CK Life Sciences International (Holdings), Inc.
|
$0.07 | -- | $672.8M | -- | $0.00 | 0% | 0.95x |
|
LJUIF
SSY Group Ltd.
|
$0.40 | -- | $1.2B | 14.08x | $0.01 | 4.63% | 2.02x |
|
RGC
Regencell Bioscience Holdings Ltd.
|
$29.17 | -- | $14.4B | -- | $0.00 | 0% | -- |
|
SBMFF
Sino Biopharmaceutical Ltd.
|
$0.84 | -- | $15B | 30.49x | $0.01 | 1.37% | 3.57x |
|
UNBSF
Uni-Bio Science Group
|
-- | -- | -- | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
HCM
HUTCHMED (China) Ltd.
|
7.07% | 0.259 | -- | 4.41x |
|
CKLSF
CK Life Sciences International (Holdings), Inc.
|
-- | 0.000 | -- | -- |
|
LJUIF
SSY Group Ltd.
|
33.22% | -0.277 | -- | 2.03x |
|
RGC
Regencell Bioscience Holdings Ltd.
|
-- | 20.934 | -- | -- |
|
SBMFF
Sino Biopharmaceutical Ltd.
|
23.1% | 0.898 | -- | 1.14x |
|
UNBSF
Uni-Bio Science Group
|
-- | 0.000 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
HCM
HUTCHMED (China) Ltd.
|
-- | -- | 46.32% | 50.64% | -- | -- |
|
CKLSF
CK Life Sciences International (Holdings), Inc.
|
-- | -- | -- | -- | -- | -- |
|
LJUIF
SSY Group Ltd.
|
-- | -- | 12.86% | 19.05% | -- | -- |
|
RGC
Regencell Bioscience Holdings Ltd.
|
-- | -- | -- | -- | -- | -- |
|
SBMFF
Sino Biopharmaceutical Ltd.
|
-- | -- | 6.83% | 8.57% | -- | -- |
|
UNBSF
Uni-Bio Science Group
|
-- | -- | -- | -- | -- | -- |
HUTCHMED (China) Ltd. vs. Competitors
-
Which has Higher Returns HCM or CKLSF?
CK Life Sciences International (Holdings), Inc. has a net margin of -- compared to HUTCHMED (China) Ltd.'s net margin of --. HUTCHMED (China) Ltd.'s return on equity of 50.64% beat CK Life Sciences International (Holdings), Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HCMHUTCHMED (China) Ltd.-- -- $1.3B CKLSFCK Life Sciences International (Holdings), Inc.-- -- -- -
What do Analysts Say About HCM or CKLSF?
HUTCHMED (China) Ltd. has a consensus price target of $21.11, signalling upside risk potential of 38.03%. On the other hand CK Life Sciences International (Holdings), Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that HUTCHMED (China) Ltd. has higher upside potential than CK Life Sciences International (Holdings), Inc., analysts believe HUTCHMED (China) Ltd. is more attractive than CK Life Sciences International (Holdings), Inc..
Company Buy Ratings Hold Ratings Sell Ratings HCMHUTCHMED (China) Ltd.9 2 1 CKLSFCK Life Sciences International (Holdings), Inc.0 0 0 -
Is HCM or CKLSF More Risky?
HUTCHMED (China) Ltd. has a beta of 0.422, which suggesting that the stock is 57.83% less volatile than S&P 500. In comparison CK Life Sciences International (Holdings), Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock HCM or CKLSF?
HUTCHMED (China) Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CK Life Sciences International (Holdings), Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. HUTCHMED (China) Ltd. pays -- of its earnings as a dividend. CK Life Sciences International (Holdings), Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HCM or CKLSF?
HUTCHMED (China) Ltd. quarterly revenues are --, which are smaller than CK Life Sciences International (Holdings), Inc. quarterly revenues of --. HUTCHMED (China) Ltd.'s net income of -- is lower than CK Life Sciences International (Holdings), Inc.'s net income of --. Notably, HUTCHMED (China) Ltd.'s price-to-earnings ratio is 4.92x while CK Life Sciences International (Holdings), Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HUTCHMED (China) Ltd. is 4.42x versus 0.95x for CK Life Sciences International (Holdings), Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HCMHUTCHMED (China) Ltd.4.42x 4.92x -- -- CKLSFCK Life Sciences International (Holdings), Inc.0.95x -- -- --
-
Which has Higher Returns HCM or LJUIF?
SSY Group Ltd. has a net margin of -- compared to HUTCHMED (China) Ltd.'s net margin of --. HUTCHMED (China) Ltd.'s return on equity of 50.64% beat SSY Group Ltd.'s return on equity of 19.05%.
Company Gross Margin Earnings Per Share Invested Capital HCMHUTCHMED (China) Ltd.-- -- $1.3B LJUIFSSY Group Ltd.-- -- $1.4B -
What do Analysts Say About HCM or LJUIF?
HUTCHMED (China) Ltd. has a consensus price target of $21.11, signalling upside risk potential of 38.03%. On the other hand SSY Group Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that HUTCHMED (China) Ltd. has higher upside potential than SSY Group Ltd., analysts believe HUTCHMED (China) Ltd. is more attractive than SSY Group Ltd..
Company Buy Ratings Hold Ratings Sell Ratings HCMHUTCHMED (China) Ltd.9 2 1 LJUIFSSY Group Ltd.0 0 0 -
Is HCM or LJUIF More Risky?
HUTCHMED (China) Ltd. has a beta of 0.422, which suggesting that the stock is 57.83% less volatile than S&P 500. In comparison SSY Group Ltd. has a beta of 0.039, suggesting its less volatile than the S&P 500 by 96.073%.
-
Which is a Better Dividend Stock HCM or LJUIF?
HUTCHMED (China) Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SSY Group Ltd. offers a yield of 4.63% to investors and pays a quarterly dividend of $0.01 per share. HUTCHMED (China) Ltd. pays -- of its earnings as a dividend. SSY Group Ltd. pays out 48.86% of its earnings as a dividend. SSY Group Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios HCM or LJUIF?
HUTCHMED (China) Ltd. quarterly revenues are --, which are smaller than SSY Group Ltd. quarterly revenues of --. HUTCHMED (China) Ltd.'s net income of -- is lower than SSY Group Ltd.'s net income of --. Notably, HUTCHMED (China) Ltd.'s price-to-earnings ratio is 4.92x while SSY Group Ltd.'s PE ratio is 14.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HUTCHMED (China) Ltd. is 4.42x versus 2.02x for SSY Group Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HCMHUTCHMED (China) Ltd.4.42x 4.92x -- -- LJUIFSSY Group Ltd.2.02x 14.08x -- --
-
Which has Higher Returns HCM or RGC?
Regencell Bioscience Holdings Ltd. has a net margin of -- compared to HUTCHMED (China) Ltd.'s net margin of --. HUTCHMED (China) Ltd.'s return on equity of 50.64% beat Regencell Bioscience Holdings Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HCMHUTCHMED (China) Ltd.-- -- $1.3B RGCRegencell Bioscience Holdings Ltd.-- -- -- -
What do Analysts Say About HCM or RGC?
HUTCHMED (China) Ltd. has a consensus price target of $21.11, signalling upside risk potential of 38.03%. On the other hand Regencell Bioscience Holdings Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that HUTCHMED (China) Ltd. has higher upside potential than Regencell Bioscience Holdings Ltd., analysts believe HUTCHMED (China) Ltd. is more attractive than Regencell Bioscience Holdings Ltd..
Company Buy Ratings Hold Ratings Sell Ratings HCMHUTCHMED (China) Ltd.9 2 1 RGCRegencell Bioscience Holdings Ltd.0 0 0 -
Is HCM or RGC More Risky?
HUTCHMED (China) Ltd. has a beta of 0.422, which suggesting that the stock is 57.83% less volatile than S&P 500. In comparison Regencell Bioscience Holdings Ltd. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock HCM or RGC?
HUTCHMED (China) Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regencell Bioscience Holdings Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. HUTCHMED (China) Ltd. pays -- of its earnings as a dividend. Regencell Bioscience Holdings Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HCM or RGC?
HUTCHMED (China) Ltd. quarterly revenues are --, which are smaller than Regencell Bioscience Holdings Ltd. quarterly revenues of --. HUTCHMED (China) Ltd.'s net income of -- is lower than Regencell Bioscience Holdings Ltd.'s net income of --. Notably, HUTCHMED (China) Ltd.'s price-to-earnings ratio is 4.92x while Regencell Bioscience Holdings Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HUTCHMED (China) Ltd. is 4.42x versus -- for Regencell Bioscience Holdings Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HCMHUTCHMED (China) Ltd.4.42x 4.92x -- -- RGCRegencell Bioscience Holdings Ltd.-- -- -- --
-
Which has Higher Returns HCM or SBMFF?
Sino Biopharmaceutical Ltd. has a net margin of -- compared to HUTCHMED (China) Ltd.'s net margin of --. HUTCHMED (China) Ltd.'s return on equity of 50.64% beat Sino Biopharmaceutical Ltd.'s return on equity of 8.57%.
Company Gross Margin Earnings Per Share Invested Capital HCMHUTCHMED (China) Ltd.-- -- $1.3B SBMFFSino Biopharmaceutical Ltd.-- -- $7.2B -
What do Analysts Say About HCM or SBMFF?
HUTCHMED (China) Ltd. has a consensus price target of $21.11, signalling upside risk potential of 38.03%. On the other hand Sino Biopharmaceutical Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that HUTCHMED (China) Ltd. has higher upside potential than Sino Biopharmaceutical Ltd., analysts believe HUTCHMED (China) Ltd. is more attractive than Sino Biopharmaceutical Ltd..
Company Buy Ratings Hold Ratings Sell Ratings HCMHUTCHMED (China) Ltd.9 2 1 SBMFFSino Biopharmaceutical Ltd.0 0 0 -
Is HCM or SBMFF More Risky?
HUTCHMED (China) Ltd. has a beta of 0.422, which suggesting that the stock is 57.83% less volatile than S&P 500. In comparison Sino Biopharmaceutical Ltd. has a beta of 0.733, suggesting its less volatile than the S&P 500 by 26.711%.
-
Which is a Better Dividend Stock HCM or SBMFF?
HUTCHMED (China) Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sino Biopharmaceutical Ltd. offers a yield of 1.37% to investors and pays a quarterly dividend of $0.01 per share. HUTCHMED (China) Ltd. pays -- of its earnings as a dividend. Sino Biopharmaceutical Ltd. pays out 65.96% of its earnings as a dividend. Sino Biopharmaceutical Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios HCM or SBMFF?
HUTCHMED (China) Ltd. quarterly revenues are --, which are smaller than Sino Biopharmaceutical Ltd. quarterly revenues of --. HUTCHMED (China) Ltd.'s net income of -- is lower than Sino Biopharmaceutical Ltd.'s net income of --. Notably, HUTCHMED (China) Ltd.'s price-to-earnings ratio is 4.92x while Sino Biopharmaceutical Ltd.'s PE ratio is 30.49x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HUTCHMED (China) Ltd. is 4.42x versus 3.57x for Sino Biopharmaceutical Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HCMHUTCHMED (China) Ltd.4.42x 4.92x -- -- SBMFFSino Biopharmaceutical Ltd.3.57x 30.49x -- --
-
Which has Higher Returns HCM or UNBSF?
Uni-Bio Science Group has a net margin of -- compared to HUTCHMED (China) Ltd.'s net margin of --. HUTCHMED (China) Ltd.'s return on equity of 50.64% beat Uni-Bio Science Group's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HCMHUTCHMED (China) Ltd.-- -- $1.3B UNBSFUni-Bio Science Group-- -- -- -
What do Analysts Say About HCM or UNBSF?
HUTCHMED (China) Ltd. has a consensus price target of $21.11, signalling upside risk potential of 38.03%. On the other hand Uni-Bio Science Group has an analysts' consensus of -- which suggests that it could fall by --. Given that HUTCHMED (China) Ltd. has higher upside potential than Uni-Bio Science Group, analysts believe HUTCHMED (China) Ltd. is more attractive than Uni-Bio Science Group.
Company Buy Ratings Hold Ratings Sell Ratings HCMHUTCHMED (China) Ltd.9 2 1 UNBSFUni-Bio Science Group0 0 0 -
Is HCM or UNBSF More Risky?
HUTCHMED (China) Ltd. has a beta of 0.422, which suggesting that the stock is 57.83% less volatile than S&P 500. In comparison Uni-Bio Science Group has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock HCM or UNBSF?
HUTCHMED (China) Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Uni-Bio Science Group offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. HUTCHMED (China) Ltd. pays -- of its earnings as a dividend. Uni-Bio Science Group pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HCM or UNBSF?
HUTCHMED (China) Ltd. quarterly revenues are --, which are smaller than Uni-Bio Science Group quarterly revenues of --. HUTCHMED (China) Ltd.'s net income of -- is lower than Uni-Bio Science Group's net income of --. Notably, HUTCHMED (China) Ltd.'s price-to-earnings ratio is 4.92x while Uni-Bio Science Group's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HUTCHMED (China) Ltd. is 4.42x versus -- for Uni-Bio Science Group. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HCMHUTCHMED (China) Ltd.4.42x 4.92x -- -- UNBSFUni-Bio Science Group-- -- -- --
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
77
RNG alert for Feb 21
RingCentral, Inc. [RNG] is up 34.37% over the past day.
Sell
9
FROG alert for Feb 21
JFrog Ltd. [FROG] is down 24.98% over the past day.
Buy
72
SNSE alert for Feb 21
Sensei Biotherapeutics, Inc. [SNSE] is up 23.81% over the past day.
